These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9107385)

  • 41. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells.
    Meng Q; Walker DM; Olivero OA; Shi X; Antiochos BB; Poirier MC; Walker VE
    Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12667-71. PubMed ID: 11058153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha.
    Pagano PJ; Chong KT
    J Infect Dis; 1995 Jan; 171(1):61-7. PubMed ID: 7528253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors.
    Nottet HS; Oteman MH; Visser MR; Verhoef J
    J Antimicrob Chemother; 1994 Feb; 33(2):366-8. PubMed ID: 7514164
    [No Abstract]   [Full Text] [Related]  

  • 45. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
    Mayers DL; Japour AJ; Arduino JM; Hammer SM; Reichman R; Wagner KF; Chung R; Lane J; Crumpacker CS; McLeod GX
    Antimicrob Agents Chemother; 1994 Feb; 38(2):307-14. PubMed ID: 8192457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
    J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
    Shafer RW; Kozal MJ; Winters MA; Iversen AK; Katzenstein DA; Ragni MV; Meyer WA; Gupta P; Rasheed S; Coombs R
    J Infect Dis; 1994 Apr; 169(4):722-9. PubMed ID: 8133086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
    Chong KT; Pagano PJ; Hinshaw RR
    Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intracellular activation and cytotoxicity of three different combinations of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
    Palmer S; Cox S
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1227-33. PubMed ID: 8573379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A new AIDS drug in evaluation].
    Fortschr Med; 1993 Aug; 111(24):12. PubMed ID: 7691696
    [No Abstract]   [Full Text] [Related]  

  • 53. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
    Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.
    Dornsife RE; St Clair MH; Huang AT; Panella TJ; Koszalka GW; Burns CL; Averett DR
    Antimicrob Agents Chemother; 1991 Feb; 35(2):322-8. PubMed ID: 1708977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
    Simonelli C; Zanussi S; Sandri S; Comar M; Lucenti A; Talamini R; Bortolin MT; Giacca M; De Paoli P; Tirelli U
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):20-7. PubMed ID: 9928725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL
    Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
    Okamoto M; Okamoto T; Baba M
    Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
    Piras G; Nakade K; Yuasa S; Baba M
    AIDS; 1997 Mar; 11(4):469-75. PubMed ID: 9084794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.